Highly specific and potently activating Vγ9Vδ2-T cell specific nanobodies for diagnostic and therapeutic applications

被引:25
|
作者
de Bruin, Renee C. G. [1 ]
Lougheed, Sinead M. [1 ]
van der Kruk, Liza [1 ]
Stam, Anita G. [1 ]
Hooijberg, Erik [2 ]
Roovers, Rob C. [3 ]
Henegouwen, Paul M. P. van Bergen En [3 ]
Verheul, Henk M. W. [1 ]
de Gruijl, Tanja D. [1 ]
van der Vliet, Hans J. [1 ]
机构
[1] Vrije Univ Amsterdam Med Ctr, Dept Med Oncol, Room 3A38,De Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands
[2] Vrije Univ Amsterdam Med Ctr, Dept Pathol, De Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands
[3] Univ Utrecht, Fac Sci, Dept Cell Biol, Padualaan 8, NL-3584 CH Utrecht, Netherlands
关键词
Nanobody; Single-domain antibody fragment; VHH; Gamma delta T cells; Flow cytometry; MACS; Immunocytochemistry; Immunotherapy; Cancer; DELTA T-CELLS; CANCER-IMMUNOTHERAPY; ANTIBODY FRAGMENTS; ANTIGEN RECEPTOR; ALBUMIN-BINDING; LIGHT-CHAINS; RECOGNITION; DOMAIN; PHOSPHOANTIGENS; MODULATION;
D O I
10.1016/j.clim.2016.06.012
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
V gamma 9V delta 2-T cells constitute the predominant subset of gamma delta-T cells in human peripheral blood and have been shown to play an important role in antimicrobial and antitumor immune responses. Several efforts have been initiated to exploit these cells for cancer immunotherapy, e.g. by using phosphoantigens, adoptive cell transfer, and by a bispecific monoclonal antibody based approach. Here, we report the generation of a novel set of V gamma 9V delta 2-T cell specific VHH (or nanobody). VHH have several advantages compared to conventional antibodies related to their small size, stability, ease of generating multispecific molecules and low immunogenicity. With high specificity and affinity, the anti-V gamma 9V delta 2-T cell receptor VHHs are shown to be useful for FACS, MACS and immunocytochemistry. In addition, some VHH were found to specifically activate V gamma 9V delta 2-T cells. Besides being of possible immunotherapeutic value, these single domain antibodies will be of great value in the further study of this important immune effector cell subset. (C) 2016 The Authors. Published by Elsevier Inc.
引用
收藏
页码:128 / 138
页数:11
相关论文
共 50 条
  • [31] The Molecular Basis for Modulation of Human Vγ9Vδ2 T Cell Responses by CD277/Butyrophilin-3 (BTN3A)-specific Antibodies
    Palakodeti, Aparna
    Sandstrom, Andrew
    Sundaresan, Lakshmi
    Harly, Christelle
    Nedellec, Steven
    Olive, Daniel
    Scotet, Emmanuel
    Bonneville, Marc
    Adams, Erin J.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2012, 287 (39) : 32780 - 32790
  • [32] Development and Selection of the Human Vγ9Vδ2+ T-Cell Repertoire
    Willcox, Carrie R.
    Davey, Martin S.
    Willcox, Benjamin E.
    FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [33] IL-21 promotes the development of a CD73-positive Vγ9Vδ2 T cell regulatory population
    Barjon, Clement
    Michaud, Henri-Alexandre
    Fages, Angeline
    Dejou, Cecile
    Zampieri, Alexandre
    They, Laetitia
    Gennetier, Aurelie
    Sanchez, Francoise
    Gros, Laurent
    Eliaou, Jean-Francois
    Bonnefoy, Nathalie
    Lafont, Virginie
    ONCOIMMUNOLOGY, 2018, 7 (01):
  • [34] Human Vγ9Vδ2 T cell expansion and their cytotoxic responses against cholangiocarcinoma
    Sawaisorn, Piamsiri
    Gaballa, Ahmed
    Saimuang, Kween
    Leepiyasakulchai, Chaniya
    Lertjuthaporn, Sakaorat
    Hongeng, Suradej
    Uhlin, Michael
    Jangpatarapongsa, Kulachart
    SCIENTIFIC REPORTS, 2024, 14 (01)
  • [35] Targeting myeloma–osteoclast interaction with Vγ9Vδ2 T cells
    Qu Cui
    Hironobu Shibata
    Asuka Oda
    Hiroe Amou
    Ayako Nakano
    Kenichiro Yata
    Masahiro Hiasa
    Keiichiro Watanabe
    Shingen Nakamura
    Hirokazu Miki
    Takeshi Harada
    Shiro Fujii
    Kumiko Kagawa
    Kyoko Takeuchi
    Shuji Ozaki
    Toshio Matsumoto
    Masahiro Abe
    International Journal of Hematology, 2011, 94 : 63 - 70
  • [36] Vγ9Vδ2 T-cell immunotherapy in blood cancers: ready for prime time?
    Giannotta, Claudia
    Autino, Federica
    Massaia, Massimo
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [37] Vδ2 T-cell engagers bivalent for Vδ2-TCR binding provide anti-tumor immunity and support robust Vγ9Vδ2 T-cell expansion
    King, Lisa A.
    de Jong, Milon
    Veth, Myrthe
    Hulsik, David Lutje
    Yousefi, Parsa
    Iglesias-Guimarais, Victoria
    van Helden, Pauline M.
    de Gruijl, Tanja D.
    van der Vliet, Hans J.
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [38] Beyond CAR T cells: Engineered Vγ9Vδ2 T cells to fight solid tumors
    Rafia, Chirine
    Harly, Christelle
    Scotet, Emmanuel
    IMMUNOLOGICAL REVIEWS, 2020, 298 (01) : 117 - 133
  • [39] Directing the migration of serum-free, ex vivo-expanded Vγ9Vδ2 T cells
    Parwani, Kiran K.
    Branella, Gianna M.
    Burnham, Rebecca E.
    Burnham, Andre J.
    Bustamante, Austre Y. Schiaffino
    Foppiani, Elisabetta Manuela
    Knight, Kristopher A.
    Petrich, Brian G.
    Horwitz, Edwin M.
    Doering, Christopher B.
    Spencer, H. Trent
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [40] Improving CLL Vγ9Vδ2-T-cell fitness for cellular therapy by ex vivo activation and ibrutinib
    de Weerdt, Iris
    Hofland, Tom
    Lameris, Roeland
    Endstra, Sanne
    Jongejan, Aldo
    Moerland, Perry D.
    de Bruin, Renee C. G.
    Remmerswaal, Ester B. M.
    ten Berge, Ineke J. M.
    Liu, Nora
    van der Stelt, Mario
    Faber, Laura M.
    Levin, Mark-David
    Eldering, Eric
    Tonino, Sanne H.
    de Gruijl, Tanja D.
    van der Vliet, Hans J.
    Kater, Arnon P.
    BLOOD, 2018, 132 (21) : 2260 - 2272